Physician profile
Hanh Pham
NPI 1659931939
$9,141.41
in general payments reported to CMS, 2019-2025
42 companies · $2,667 in 2025
The $2,667 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $1,528 · 2023: $1,842 · 2024: $2,135 · 2025: $2,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,486 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,486.06 |
| Education | $157.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,873.64 | 2022-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $795.47 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mallinckrodt Hospital Products INC. | $593.10 | 2022-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $540.05 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Viiv Healthcare Company | $500.06 | 2021-2022 | |
| Baxter Healthcare | $403.57 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $360.75 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $310.16 | 2024-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $304.44 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $274.91 | 2025 | Dupixent |
| United Therapeutics Corporation | $264.58 | 2022-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.14 | 2022-2025 | Ofev, Jascayd, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $214.74 | 2022-2025 | Glassia |
| Astellas Pharma US INC | $211.76 | 2021-2022 | |
| Mylan Specialty L.P. | $202.28 | 2022-2024 | Yupelri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $181.07 | 2023-2024 | Tezspire |
| Melinta Therapeutics, LLC | $175.71 | 2021-2022 | |
| Grifols USA, LLC | $174.92 | 2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $174.23 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $166.17 | 2021-2023 | Dificid, Zerbaxa, Recarbrio |
| Philips North America LLC | $143.89 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Gilead Sciences, INC. | $118.88 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $115.50 | 2021 | |
| Abbvie INC. | $112.55 | 2021-2024 | |
| Insmed, INC. | $100.70 | 2024-2025 | Arikayce |
| Vifor Pharma, INC. | $88.08 | 2024-2025 | Zemaira |
| Bayer Healthcare Pharmaceuticals INC. | $83.93 | 2022-2023 | |
| Lilly USA, LLC | $62.86 | 2025 | Zepbound, Mounjaro |
| Genentech USA, INC. | $48.51 | 2022 | |
| Paratek Pharmaceuticals, INC. | $43.19 | 2021 | |
| Merz North America, INC. | $39.46 | 2023 | |
| Axsome Therapeutics, INC. | $39.29 | 2024-2025 | Sunosi |
| Electromed, INC. | $37.51 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.98 | 2022 | |
| Liquidia Technologies, INC. | $19.28 | 2025 | Yutrepia |
| 3b Medical, INC. | $18.19 | 2025 | Luna |
| Daiichi Sankyo INC. | $17.17 | 2021 | |
| Janssen Biotech, INC. | $16.88 | 2021 | |
| Inspire Medical Systems, INC. | $16.84 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $15.82 | 2022 | |
| Shionogi INC | $15.24 | 2021 | |
| Theratechnologies INC. | $14.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanh Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.